William Blair analysts have initiated coverage of Thermo Fisher and expect the company to build on its status as the “partner of choice” for the biopharma industry.
The Chinese CRDMO attributed the results in the first half of 2025 to operational efficiency gains, technology platform expansion, and facility ramp-ups in Europe.